{"id":"W1242366555","doi":"10.1007/s00415-015-7834-0","title":"Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis","year":2015,"lang":"en","type":"article","venue":"Journal of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital; Montreal Neurological Institute and Hospital","funders":"Novartis Pharma; National Research Foundation; Actelion Pharmaceuticals; Novartis; Teva Pharmaceutical Industries; Serono Symposia International Foundation","keywords":"Fingolimod; Medicine; Expanded Disability Status Scale; Multiple sclerosis; Discontinuation; Adverse effect; Placebo; Internal medicine; Randomized controlled trial; Neurology; Natalizumab; Clinical trial; Pathology; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008501716,0.0001614403,0.0007594167,0.0003727122,0.00004960915,0.000009771295,0.0001240295,0.0001077355,0.000006144926],"category_scores_gemma":[0.00421905,0.0001238634,0.00006525452,0.0001900312,0.0001463989,0.000111186,0.0002855922,0.0005456374,0.000001559567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006643926,"about_ca_system_score_gemma":0.00006692144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004820339,"about_ca_topic_score_gemma":0.000635593,"domain_scores_codex":[0.9976115,0.0003900111,0.0009075266,0.0003128715,0.000501802,0.0002763037],"domain_scores_gemma":[0.9976443,0.0008503202,0.0005572823,0.0003102768,0.0003839721,0.0002538314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06058539,0.00457518,0.5608758,0.00003632449,0.0001569114,0.00137264,0.005691895,0.0001381888,0.3572047,3.05995e-7,0.0008353949,0.008527243],"study_design_scores_gemma":[0.06302323,0.009928091,0.92396,0.0001612804,0.00007929196,0.0001325175,0.0002289029,0.001189732,0.001177365,0.00001079693,0.00003369892,0.00007507831],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971013,0.0004423007,0.00001086043,0.001732417,0.0002290278,0.0004422022,0.00001987881,0.00000772486,0.00001425691],"genre_scores_gemma":[0.9988882,0.0004512233,0.0002916036,0.0001737804,0.0001516664,0.000004557666,0.000005527744,0.0000199286,0.00001350022],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3630842,"threshold_uncertainty_score":0.5051003,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1744770482669709,"score_gpt":0.3546205121302032,"score_spread":0.1801434638632323,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}